Tuesday, November 29, 2011
Inviragen Inc., of Fort Collins, Colo., started a Phase II randomized, double-blind, placebo-controlled study of DENVax, an investigational dengue vaccine based on an attenuated DEN-2 virus. The trial will test the safety and immunogenicity of DENVax in multiple age groups in dengue-endemic countries. Data from a Phase I study demonstrated the vaccine is safe and well tolerated and immunogenic in dengue-naive adults.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.